Pharvaris reports sustained efficacy in HAE treatment study

ZUG, Switzerland - Pharvaris (NASDAQ:PHVS), a biopharmaceutical company, has announced long-term data supporting the sustained efficacy and safety of its drug candidate deucrictibant for the treatment of hereditary angioedema (HAE). The data, presented at the Bradykinin Symposium 2024 in Berlin, indicates a significant reduction in HAE attack rates with deucrictibant.

The company's prophylactic extension study showed that patients experienced a 93% reduction in attack rates over a period exceeding one year. The study also reported a median attack rate of zero per month and a mean of 99% attack-free days. Additionally, patient satisfaction with the treatment's effectiveness and tolerability was high, according to the Angioedema Control Test results.

On-demand treatment data from the RAPIDe-2 study revealed that deucrictibant immediate-release capsules provided median symptom relief in approximately 1.1 hours, with the majority of attacks resolving within 24 hours. These results suggest that deucrictibant may offer a rapid and effective option for on-demand management of HAE attacks.

Safety assessments have consistently reaffirmed the tolerability of deucrictibant, with no new safety concerns arising from the studies. Furthermore, cardiovascular safety evaluations have shown no impact on heart parameters, bolstering the drug's safety profile.

Pharvaris is advancing deucrictibant through late-stage clinical development, with ongoing pivotal Phase 3 studies for both prophylactic and on-demand treatment settings. The company aims to provide a novel oral therapy option for individuals affected by HAE, potentially improving their quality of life and disease management.

The reported data is based on a press release statement from Pharvaris and has been presented at a scientific symposium, underscoring the potential of deucrictibant as a preferred therapy for managing HAE. As the drug progresses through clinical trials, further updates on its efficacy and safety are anticipated.

In other recent news, Pharvaris, a biopharmaceutical company, is making significant strides in advancing its drug candidate deucrictibant. The company has announced the initiation of a pivotal Phase 3 clinical trial, CHAPTER-3, for deucrictibant, intended for the prophylactic treatment of hereditary angioedema (HAE). Furthermore, Pharvaris plans to explore the use of deucrictibant for treating acquired angioedema due to C1-inhibitor deficiency, following promising results from a trial conducted at Amsterdam University Medical Center.

In addition to these developments, Oppenheimer has raised its price target for Pharvaris following a comprehensive review of the company's recent clinical advancements and future trajectory. This adjustment reflects confidence in deucrictibant's potential market opportunity.

In other company news, Pharvaris has appointed David Nassif as its new Chief Financial Officer. With over three decades of financial management expertise, Nassif is expected to refine Pharvaris's financial strategies and operations. These recent developments underscore Pharvaris's commitment to advancing its clinical studies while also strengthening its financial strategy.

InvestingPro Insights

As Pharvaris (NASDAQ:PHVS) continues to make strides in the clinical development of deucrictibant, with promising long-term data presented at the Bradykinin Symposium, investors are closely monitoring the company's financial health and market performance. According to InvestingPro data, Pharvaris holds a market capitalization of approximately $934.87 million, reflecting investor sentiment and the company's perceived value in the biopharmaceutical space.

Investors considering Pharvaris should note that the company's price-to-earnings (P/E) ratio stands at -6.61, which suggests that the market currently does not expect the company to generate positive earnings in the near term. This aligns with an InvestingPro Tip indicating that analysts do not anticipate Pharvaris will be profitable this year. Moreover, the company's return on assets over the last twelve months as of Q2 2024 is -42.13%, reinforcing the challenges faced in achieving profitability.

However, not all signals are negative. Pharvaris's liquid assets exceed its short-term obligations, which could provide some financial flexibility in its operations. Additionally, two analysts have revised their earnings upwards for the upcoming period, reflecting a potential shift in expectations regarding the company's financial performance. There are 7 additional InvestingPro Tips available, offering further insights into Pharvaris's financial outlook and market behavior. For those interested in a deeper analysis, these can be found at: https://www.investing.com/pro/PHVS.

With the next earnings date scheduled for October 31, 2024, and a fair value estimation by analysts at $32.76, contrasting with the InvestingPro fair value of $16.11, investors will be keen to see whether the upcoming financial results align with the company's promising clinical trial outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.